INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Eric Angevin; Todd M Bauer; Catherine E Ellis; Hui Gan; Rigel Hall; Aaron Hansen; Axel Hoos; Roxanne C Jewell; Jessica Katz; Juan Martin-Liberal; Michele Maio; Patrick A Mayes; Jolly Mazumdar; Michael Millward; Danny Rischin; Jan H Schellens; Sapna Yadavilli; Helen Zhou

Conference Proceedings

INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Eric Angevin, Todd M Bauer, Catherine E Ellis, Hui Gan, Rigel Hall, Aaron Hansen, Axel Hoos, Roxanne C Jewell, Jessica Katz, Juan Martin-Liberal, Michele Maio, Patrick A Mayes, Jolly Mazumdar, Michael Millward, Danny Rischin, Jan H Schellens, Sapna Yadavilli, Helen Zhou

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2017

DOI: 10.1158/1538-7445.AM2017-CT039

Abstract

Abstract Background Inducible T cell Co-Stimulator (ICOS), a member of the CD28/B7/CTLA immunoglobulin receptor superfamily, is expressed on T cells after engagement with cognate antigen and activation. ICOS provides a co-stimulatory signal augmenting T cell proliferation, cytokine production, cytotoxic function and survival. GSK3359609 is a humanized IgG4 antibody selected for its potent binding agonist activity against human ICOS. Rationale for targeting ICOS with GSK33359609 as a monotherapy and in combination with other cancer immunotherapies such as pembrolizumab is supported by preclinical evidence. Methods INDUCE-1 is a first in human study evaluating saf..

View full abstract